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Abstract Polymorphisms of G-protein coupled receptor
(GPCR) genes are associated with disease risk and modification,
and the response to receptor-directed therapy. Genomic sequen-
cing (V1700 automated runs) from as many as 120 chromo-
somes from 60 multiethnic individuals was performed to confirm
non-synonymous coding polymorphisms reported in the dbSNP
database from 25 randomly selected GPCR genes. These
polymorphisms were in regions of the receptors responsible for
structural integrity, ligand binding, G-protein coupling and
phosphoregulation. However, most of these putative polymorph-
isms could not be confirmed (false positive rate of 68%). Based
on these results, we suggest that the variability of the superfamily
is not well defined, and we caution against exclusive reliance on
databases for selection of candidate GPCR polymorphisms for
disease association and pharmacogenetic studies. ß 2002 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
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1. Introduction
G-protein coupled receptors (GPCRs) represent one of the
largest families of genes in the genome, and carry out a di-
verse array of signaling including autocrine, hormonal, para-
crine and central and peripheral neurotransmission [1]. As a
superfamily, GPCRs provide integrated, dynamic, and £exible
signaling to maintain homeostasis and to respond to physio-
logic and pathologic events. As such, pharmacologic agents
which serve to activate, or antagonize, GPCR signaling are
common. Indeed, V60% of therapeutics currently target
GPCRs [2].
The signaling of GPCRs in vivo and in vitro (from ex-
tracted tissues), as well as the clinical response to agonists
and antagonists, displays a large degree of interindividual
variation [3^6]. For example, treatment of congestive heart
failure with L-adrenergic receptor antagonists has been found
to be highly variable, with no consistent clinical parameter
being predictive of a favorable response [4]. Some of the var-
iability observed with GPCR agonists or antagonists is
thought to be due to polymorphisms of the genes encoding
these receptors. In asthma, the response to the L-agonist al-
buterol acting at airway L2-adrenergic receptors is also highly
variable [7], and calculations have revealed that V50% of this
variability has a genetic basis [6]. Besides potential pharma-
cogenetic loci, GPCR polymorphisms have also been found to
be low-level risk factors for disease [8], and to act as disease
modi¢ers [9]. While initial attention has focused on non-syn-
onymous polymorphisms in the coding region of genes (i.e.
polymorphisms that alter the encoded amino acid), it is clear
that polymorphisms in promoter and untranslated regions
may be responsible for altered expression or regulation as
well [10].
Given such variability, the role of GPCRs in normal and
pathologic states, and their use as targets for therapeutics, an
understanding of the degree of genetic variability within their
genes is necessary. In the process of carrying out recent stud-
ies on the signaling properties of polymorphic GPCRs, we
noted that the available public databases which catalog poly-
morphisms appeared to have a high false positive rate. In the
current study, we have utilized an adequately powered, multi-
ethnic index repository of genomic DNA, and a set of ran-
domly selected GPCRs to ascertain the validity of polymor-
phisms reported in the database dbSNP, the largest such
collection of single nucleotide polymorphisms. The focus
was on non-synonymous coding block variants, since struc-
ture/function studies have de¢ned functional regions of many
GPCRs, and thus implications of the genetic variability could
be inferred.
2. Materials and methods
2.1. GPCR genes interrogated
On 8 August 2001 we delineated 142 GPCRs from the genome with
known ligands (i.e. not orphan receptors). The opsins and the olfac-
tory receptors were also excluded. Of these, 119 had a human se-
quence in the National Center for Biotechnology Information
(NCBI) database with an entry in the dbSNP database (http://
www.ncbi.nlm.nih.gov/SNP) [11]. These genes were ordered using a
random number generator and the coding regions of each examined
for sequence variation in dbSNP. In order for the study to adequately
represent the superfamily, coding region genes containing either one
or two non-synonymous polymorphisms (but not more than two)
were selected for study until 25 GPCR genes (V20% of the 119
characterized human GPCRs) were identi¢ed. This resulted in 36
polymorphisms reported in dbSNP which we targeted for veri¢cation.
The non-synonymous nature of the polymorphism was con¢rmed by
genomic reconstruction and translation using the indicated NCBI
reference sequence (RefSeq).
2.2. Genomic DNA samples
Genomic DNA derived from 60 individuals was used for the study
and consisted of samples from 20 Caucasians, 20 African-Americans,
and 20 Asians. The samples were obtained from the Coriell Institute
for Medical Research (Camden, NJ, USA). Using the equation:
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P  1313f 2n
where P is the probability of detecting a polymorphism, f is the fre-
quency of the variant, and n is the number of individuals sampled
(2n = number of chromosomes), it can be calculated that DNA sam-
ples from 60 individuals provides a 95% probability of detecting poly-
morphisms with allele frequencies as low as 0.025, and a 90% prob-
ability of detection at allele frequencies as low as 0.018. The samples
were initially sequenced within a 30-sample cohort of 10 Caucasians,
10 African-Americans, and 10 Asians. If the polymorphisms provided
by dbSNP were found, then no further sequencing was carried out.
If not, the additional 30 samples were sequenced. Unequivocal se-
quence could not be obtained for two of the 36 SNPs. Thus, the
results discussed represent 34 reported polymorphisms from 25
GPCR genes.
2.3. Sequencing
PCR primers were designed based on the reference sequence using
the program Amplify 1.2 (Madison, WI, USA) with the expected
polymorphism to be within 100^200 bases of the ampli¢ed sequence
start site. PCR products were 300^400 bp in size. Primers also in-
cluded sequences corresponding to M13 forward (321) and M13 re-
verse universal sequencing primers so that the same sequencing prim-
ers could be used for all genes. Such an approach also provides for
dye-primer sequencing chemistry, which in our experience results in
higher quality data than dye-terminator sequencing. PCR reactions
were optimized using the PCR optimizer kit (Invitrogen Life, Carls-
bad, CA, USA) and includedV100 ng genomic DNA, 5 pmol of each
sense and antisense primers, 0.8 nM dNTPs, 5 Wl 5U bu¡er, þ 10%
DMSO, and 0.5 U platinum taq DNA polymerase in 20 Wl reaction
volume. PCR cycling started at 94‡C for 4 min, followed by 35 cycles
at 94‡C for 30 s, 55^65‡C for 30 s, and 72‡C for 30 s, with a ¢nal
extension at 72‡C for 7 min. PCR products were diluted to 5 ng/Wl
prior to dye-primer cycle sequencing (ABI Prism, Foster City, CA,
USA). For each PCR product, four separate reactions were performed
to obtain sequence. Reactions consisted of 0.4 or 0.8 pmol of each
dye-labeled primer (FAM to use with d/ddCTP mix, JOE to use with
d/ddATP mix, TAMRA to use with d/ddGTP mix, and ROX to use
with d/ddTTP mix), 1 Wl of the appropriate d/ddNTP mix, 5 ng DNA,
0.625 U Amplitaq DNA polymerase FS, in a bu¡er containing 80 mM
Tris^HCl, pH 9.0 and 2 mM MgCl2. Reactions were subjected to 15
cycles at 96‡C for 10 min, 55‡C for 5 s, and 70‡C for 60 s, followed by
ethanol precipitation. Samples were subsequently resuspended in de-
ionized formamide and heated to 90‡C for 2 min prior to loading onto
a 6% polyacrylamide gel for analysis using the ABI Prism 377 DNA
sequencer.
2.4. Polymorphism detection
Sequence passed quality control if there were unequivocal base calls
at the putative polymorphic site and the 5P and 3P £anking sequence.
(Base calls of s 99% for the entire PCR product, equivalent to a
PHRED score of 20, were typical.) In addition, each chromatogram
was inspected individually for con¢rmation. Particular attention was
paid to the potential for heterozygosity, which with this technique is
readily revealed by overlapping peaks with V1/2 the expected peak
height and is in the context of a low background [12]. For initial
orientation and polymorphism identi¢cation, alignment with the refer-
ence sequence was carried out using MacVector 7.0 (Oxford Molec-
ular, Madison, WI, USA). If the putative polymorphism was not
detected in the ¢rst 30 samples using forward sequencing reactions,
then the additional 30 samples were sequenced using the reverse M13
primer.
Table 1
Non-synonymous G-protein coupled receptor polymorphisms interrogated from the NCBI dbSNP database
Gene symbol Rs NCBI RefSeq Nucleotide position Con¢rmed
ADORA2A 4 990 NM_000675 1 180 3
ADORA2A 4 530 NM_000675 430 3
AGTR1 1 801 021 NM_004835 1 106 3
AGTR1 1 064 533 NM_004835 1 245 3
AGTR2 5 191 NM_000686 904 +
AGTR2 1 042 860 NM_000686 965 3
BDKRB2 1 046 248 NM_000623 40 +
BRS3 5 232 NM_001727 306 3
BRS3 5 234 NM_001727 634 3
CALCR 1 801 197 NM_001742 1 377 +
CCKBR 1 805 001 NM_00731 956 3
DRD1 5 331 NM_000794 595 3
DRD2 1 800 496 NM_000795 961 3
DRD2 1 110 977 NM_000795 1 084 3
DRD4 1 800 443 NM_000797 581 +
DRD5 1 800 762 NM_000798 989 3
F2R 5 893 NM_001992 840 3
GALNR 5 376 NM_001480 1 773 +
GALNR 5 377 NM_001480 1 797 +
HTR1D 6 299 NM_000864 837 +
HTR1E 6 303 NM_000865 1 351 3
HTR2C 6 318 NM_000868 796 +
IL8RB 1 805 038 NM_001557 646 3
MTNR1A 1 800 884 NM_005958 502 3
MTNR1A 1 800 885 NM_005958 192 3
OXTR 810 568 NM_000916 1 439 3
OXTR 237 901 NM_000916 809 3
PTGER1 1 057 362 NM_000955 285 3
PTGER3 5 670 NM_000957 736 3
SSTR3 229 568 M96738.1 1 329 +
SSTR5 169 068 NM_001053 1 004 +
TRHR 5 774 D16845 42 3
TSHR 1 991 517 NM_000369 2 281 +
TSHR 1 054 708 NM_000369 1 901 3
Entries are the gene symbol from Human Genome Organization (HUGO), the dbSNP unique reference identi¢er (Rs ), the reference sequence
(RefSeq) as identi¢ed by NCBI, and the nucleotide position of each polymorphism within the NCBI RefSeq. A plus sign (+) indicates that, in
the current study, the polymorphism was con¢rmed, and a minus sign (3) indicates a lack of con¢rmation.
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3. Results and discussion
Clinical, cell-based, and transgenic mouse models of poly-
morphic variation in a few well-studied GPCRs have revealed
that alteration in receptor expression or function can have
important implications for human disease in at least three
broad categories: risk factors for disease, disease modi¢ca-
tion, and alteration of the response to receptor-directed ther-
apy.
In the current report, we assess the utility of the dbSNP
database as a resource for identi¢cation of non-synonymous
polymorphisms in GPCR genes. A relatively large number of
genomic DNA samples (representing as many as 120 chromo-
somes) from a multiethnic cohort were interrogated at 34
putative polymorphic sites identi¢ed in dbSNP in 25 GPCR
coding regions. Ultimately, s 1700 sequencing runs were an-
alyzed. The 25 random GPCR genes investigated are shown in
Table 1. As anticipated, they represent a diverse range of
subclasses and signal transduction pathways. The approxi-
mate locations of the amino acids a¡ected by the putative
34 non-synonymous polymorphisms within a prototypic
GPCR is depicted in Fig. 1. Putative substitutions included
those in domains responsible for ligand binding (transmem-
brane domains), G-protein coupling (second and third intra-
cellular loops and proximal cytoplasmic tail), phosphorylation
by kinases such as protein kinase A, protein kinase C, and
GPCR kinases (third intracellular loop and cytoplasmic tail),
and overall receptor integrity (intracellular and extracellular
loops).
Potentially, then, in considering development of new ago-
nists or antagonists for a given receptor, the presence of many
of these polymorphisms would be of signi¢cant concern. In-
deed, even single amino acid substitutions within conforma-
tionally sensitive domains have been shown to dramatically
alter receptor properties. For example, a polymorphism of the
L2-adrenergic receptor gene which results in a conservative
Thr to Ile substitution in the fourth transmembrane domain
of the receptor alters high- and low-a⁄nity agonist binding,
with a signi¢cant loss of receptor function [13]. Similarly, a
Gly to Arg substitution in a Gs coupling domain due to a
polymorphism in the L1-adrenergic receptor gene results in a
marked enhancement of receptor coupling to Gs and stimu-
lation of adenylyl cyclase [14]. The same potential phenotypes
evoked by these putative polymorphisms in these GPCR genes
could also have important implications relative to genetic risk
factors for disease or disease modi¢ers.
However, we found that the majority of the coding non-
synonymous polymorphisms of GPCRs in dbSNP that were
interrogated are likely erroneous. As shown in Fig. 2, only
32% of these putative polymorphisms could be con¢rmed
(false positive rate of 68%). There was no relationship between
the base context of the surrounding region and false positives
(mean uncon¢rmed GC content of 56% vs. 52% GC content
of con¢rmed polymorphisms). The number of chromosomes
assayed by the submitter to dbSNP also did not appear to be
a factor (mean 61 chromosomes for uncon¢rmed and 72 chro-
mosomes for con¢rmed polymorphisms). There was a rela-
tionship between the allele frequency and whether a polymor-
phism was con¢rmed. In the con¢rmed group, when reported,
the mean ( þ S.E.M.) allele frequency was 0.154 þ 0.054 vs.
0.043 þ 0.004 for the uncon¢rmed entries (P = 0.02).
The dbSNP database was established as a public resource in
September 1998 by the NCBI, in collaboration with the Na-
tional Human Genome Research Institute, as a general cata-
log of genome variation [11]. The contents of this database are
cross-linked to records in other information resources such as
GenBank, LocusLink, the human genome sequence, and Pub
Med. Most (s 99%) of nucleotide sequence variations in this
database are SNPs; however, small insertions/deletions, mi-
crosatellite repeat variation, and retrotransposable element
insertions are represented [15]. At the time this study was
initiated, dbSNP contained 1 805 951 unique human sequence
variants.
Examples of GPCR polymorphisms that are risk factors for
disease are the studies showing that the Arg16CGly and
Gln27CGln polymorphisms of the L2-adrenegic receptor
are associated with hypertension [8]. These results are consis-
tent with the altered vasoreactivity to L-agonists of individuals
with certain L2-adrenergic receptor genotypes [16,17], as well
as the in vitro studies in transfected cells [18,19]. In one of the
most comprehensive studies to date, Boerwinkle and col-
leagues [8] have shown that the odds ratio for the occurrence
of hypertension for the Glu27 allele was 1.80. This relatively
low level of risk may be typical of common polymorphisms of
individual GPCR genes, particularly in complex diseases,
which likely involve multiple genes as well as environmental
factors.
GPCR polymorphisms have been associated with an altered
clinical phenotype in several diseases. For instance, the L1-
Fig. 1. Locations of the potential amino acid changes resulting from
34 putative SNPs within coding regions of GPCR genes as reported
in the dbSNP database. Shown is a schematic of a prototypical
GPCR, with the potential changed residues indicated as circles.
Fig. 2. Number of non-synonymous SNPs in 25 randomly selected
GPCR genes reported in the dbSNP database compared to the
number of polymorphisms con¢rmed in this study by sequence anal-
ysis. The false positive rate was 68%.
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adrenergic receptor Ser49CGly polymorphism imparts en-
hanced agonist-promoted downregulation in transfected cells
[20]. In patients with congestive heart failure, the Gly49 re-
ceptor appears to provide a protective e¡ect [21], with V50%
lower ¢ve-year mortality compared to those with Ser49. This
is consistent with the notion that L1-adrenergic downregula-
tion is protective against the high levels of catecholamines that
typically occur with the syndrome.
Common polymorphisms which alter the response to drugs
have the potential to segregate populations so as to optimize
therapy. Such pharmacogenetic loci are well de¢ned for cer-
tain drug metabolism enzymes [22], but the ¢eld is only begin-
ning to be explored with GPCR polymorphisms. The altered
bronchodilatory response to L-agonist, and tachyphylaxis to
its continued use, in the treatment of asthma appears to be
in£uenced by L2-adrenergic receptor coding and 5P upstream
polymorphisms [7,10].
In this study we have assessed the usefulness of the dbSNP
database for identi¢cation of non-synonymous coding poly-
morphisms of GPCRs. Of note, the relatively low allele fre-
quencies for these non-synonymous polymorphisms of GPCR
genes are consistent with data from random genes [23] which
show thatV60% of all non-synonymous polymorphisms have
allele frequencies of 6 0.05. This prevalence of low-allele-fre-
quency non-synonymous polymorphisms further emphasizes
the need for highly accurate databases. Our ¢ndings from
the current study indicate a high number of false positive
polymorphisms in this group of important signaling genes in
dbSNP, which amounts to a positive predictive value of only
32%. It thus appears that polymorphisms identi¢ed only by
dbSNP may not be reliable candidates for resequencing in
clinical studies. Such e¡orts might result in negative associa-
tion studies and the given GPCR gene not further considered.
This could represent a signi¢cant error in gene selection for
such studies. In addition, while we have no way of assessing
false negative GPCR polymorphisms in the database, they
may be common as well, particularly for non-synonymous
polymorphisms where the allele frequency is low. Of note,
our study is con¢ned to GPCR non-synonymous SNPs with
relatively low allele frequencies, and may not be applicable to
polymorphisms in other genes or regions of genes, particularly
if allele frequencies are higher [24].
We recognize the tremendous accomplishments of the Hu-
man Genome Project [25], and the substantial contributions of
e¡orts aimed at understanding human genetic variability that
have been associated with this and other e¡orts [23,26,27].
Our current report thus represents a cautionary note that at
least within the GPCR superfamily, there is a high degree of
false positive non-synonymous polymorphisms in the dbSNP
public database. As such, the extent or degree of genetic var-
iation in the superfamily is not well de¢ned. And, our results
emphasize that when considering a GPCR gene for polymor-
phisms, diligence in resequencing the entire region(s) of inter-
est in a multiethnic cohort of adequate size is necessary.
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